European Medicines Agency
ema.europa.eu Imported from official source
European Union body; safety publications from its own official source.
Publications 20
-
EU recommendations for 2026/2027 seasonal flu vaccine composition
The recommendations were updated and published on the following dates: 17 November 2026: to include a recommendation for mRNA (nucleic acid) influenza vaccines. Annex I…
Announcement Safety -
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
Seven new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended seven medicines for approval at its November 2026 meeting.The committee…, CHMP statistics Key figures ...
Announcement Safety -
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 November 2026
CVMP opinions on veterinary medicinal products Further to the re-examination of the opinion adopted by the Committee during its June 2026 meeting, the Committee adopted a…
Announcement Safety -
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 26 - 29 October 2026
PRAC starts review of depression and anxiety medicine Deanxit (flupentixol/melitracen)PRAC has started a review of Deanxit, a fixed-dose combination medicine for treating…, Agenda Agenda of the PRA...
Announcement Safety -
EMA closed on All Souls' Day, 2 November
EMA’s office is closed on Monday 2 November, to mark All Souls' Day. The office reopens at 08:30 on Tuesday 3 November.The product emergency hotline is available outside…
Announcement -
AMA and EMA issue joint guidance on Ebola vaccine development
EMA’s Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely start of clinical trials for potential…
Announcement Safety -
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026
Six new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended six medicines for approval at its October 2026 meeting.Rasonque (daraxonrasib)…, CHMP statistics Key fig...
Announcement Safety -
EMA recommends authorisation of Rasonque for metastatic pancreatic cancer
EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Rasonque (daraxonrasib), an oral treatment for adults with…
Announcement Safety -
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 6-8 October 2026
CVMP opinions on veterinary medicinal productsThe Committee adopted a positive opinion, in exceptional circumstances, for a marketing authorisation for Bovilis Lumpyvax (lumpy…
Announcement Safety -
Clinical trial applications advice pilot becomes permanent
The Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which helps sponsors prepare clinical trial applications, will become a permanent initiative from January 2027.…
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28 September - 1 October
At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities to manage the safety of medicines, including the assessment of safety…, Agenda Agenda of t...
-
Advice on ‘end-of-year’ submission dates for type I variations in 2026
Marketing authorisation holders wishing to receive an outcome in 2026 should submit type IA annual updates, individual type IA and type IAIN variations, and super-groupings…
Announcement Safety -
EMA Management Board: highlights of September 2026 meeting
Mid-year report 2026 from the Executive DirectorEMA presented results and achievements of its operations for the first half of 2026 to the Management Board. Between January and…
Announcement -
Global regulators call for advancing alternatives to animal testing across the medicine lifecycle
EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and…
-
Executive Director speech at EMA women’s health multi-stakeholder workshop
Amsterdam, 28 September 2026Check against delivery (The published text is based on the prepared speech. Minor differences may have occurred during delivery)Good morning,…
Announcement Source page stopped responding -
Women are missing from medicines development: EMA’s roadmap for change
By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This…, Women are still missi...
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026
12 new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended 12 medicines for approval at its September 2026 meeting.The committee recommended…, CHMP statistics Key f...
Announcement Safety -
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-10 September 2026
CVMP opinions on veterinary medicinal products The Committee adopted a positive opinion for a marketing authorisation for Cirbloc, for the active immunisation of pigs from…
Announcement Safety -
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026
Review will assess risk of low blood phosphate levels and related bone problems with injectable iron medicinesEMA’s safety committee, PRAC, has started a review of injectable…, Agenda Agenda of the...
-
New EU supply chain to end Visudyne shortage
A new supply chain for Visudyne (verteporfin) has been put in place in the European Union (EU), marking an important step towards resolving a long-standing shortage of the…, This situation shows th...
Announcement Safety